Natixis Advisors, L.P. Lexicon Pharmaceuticals, Inc. Transaction History

Natixis Advisors, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	BUY	$1.3 - $3.58 $111,922 - $308,216	86,094 New	86,094 $207,000
Q2 2023 Aug 15, 2023	SELL	$2.15 - $3.49 $172 - $279	-80 Reduced 0.09%	87,425 $200,000
Q1 2023 May 11, 2023	BUY	$1.99 - $2.68 $174,134 - $234,513	87,505 New	87,505 $213,000
Q3 2022 Nov 14, 2022	BUY	$1.94 - $3.43 $171,517 - $303,249	88,411 New	88,411 $212,000
Q1 2022 May 12, 2022	SELL	$1.95 - $3.89 $183,239 - $365,539	-93,969 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$3.81 - $6.16 $2,164 - $3,498	-568 Reduced 0.6%	93,969 $370,000
Q3 2021 Nov 15, 2021	SELL	$3.38 - $5.35 $703 - $1,112	-208 Reduced 0.22%	94,537 $455,000
Q2 2021 Aug 12, 2021	SELL	$4.12 - $5.87 $469 - $669	-114 Reduced 0.12%	94,745 $435,000
Q1 2021 May 05, 2021	SELL	$3.45 - $9.09 $21,162 - $55,758	-6,134 Reduced 6.07%	94,859 $556,000
Q4 2020 Feb 12, 2021	BUY	$1.05 - $3.67 $106,042 - $370,644	100,993 New	100,993 $345,000

141

238M

459K

133K

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $157M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.